The management of superficial bladder cancer: An interactive seminar

British Journal of Urology

Volumn 78, Issue 3, 1996, Pages 372-378

  McFarlane, J P ^a   Ellis, B W ^b   Harland, S J ^a  

^a INSTITUTE OF UROLOGY AND NEPHROLOGY   (United Kingdom)

^b Ashford Hospital   (United Kingdom)

Author keywords

BCG; Bladder cancer; Haematuria; Intravesical chemotherapy; Transurethral resection

Indexed keywords

BCG VACCINE; EPIRUBICIN; MITOMYCIN; PLACEBO;

AGED; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CARCINOMA IN SITU; CASE REPORT; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CYSTECTOMY; CYSTOSCOPY; ECHOGRAPHY; FEMALE; HEMATURIA; HUMAN; INTRAVENOUS UROGRAPHY; INTRAVESICAL DRUG ADMINISTRATION; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SUPERFICIAL CANCER; SYMPOSIUM; TRANSURETHRAL RESECTION; UNITED KINGDOM;

EID: 0030423174     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.00135.x     Document Type: Article

References (36)

1. Sahabudin RM. Persad RA, Mishriki F, Feneley RC. A departmental audit of patients with bladder cancer. Ann R Coll Surg Engl 1992; 74: 351-5
2. Paul AB, Collie DA, Wild SR, Chisholm GD. An integrated haematuria clinic. Br J Clin Pract 1993; 47: 128-30
3. Marazzi P. Gabriel R. The haematuria clinic. Br Med J 1994; 308: 356
4. Hasan ST, German K, Derry CD. Same day diagnostic service for new cases of haematuria-a district general hospital experience. Br J Urol 1994; 73: 152-4
5. Spencer J, Lindsell D, Mastorakou I. Ultrasonography compared with intravenous urography in the investigation of adults with haematuria. Br Med J 1990; 301: 1074-6
6. Aslaksen A, Gadeholt G, Gothlin JH. Ultrasonography versus intravenous urography in the evaluation of patients with microscopic haematuria. Br J Urol 1990: 66: 144-7
7. Loosemore TM. Woodhouse CR. Shearer RJ. Role of ultrasound in the investigation of haematuria after normal intravenous urography and cystoscopy. Eur Urol 1991: 19: 6-7
8. McLoughlin J, Williams J, Patel PR. The normal IVU: a trap for the unwary. Br JClin Pract 1990; 44: 663-5
9. Ritchie CD, Bevan EA. Collier SJ. Importance of occult haematuria found at screening. Br Med J Clin Res Ed 1986: 292: 681-3
10. Britton JP. Dowell AC, Whelan P. Dipstick haematuria and bladder cancer in men over 60: results of a community study. Br Med J 1989: 299: 1010-2
11. Schröder FH. Microscopic haematuria. Br Med J 1994: 309: 70-2
12. Kiemeney LA, Witjes JA, Heijbroek RP, Debruyne FM, Verbeek AL. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur J Cancer 1994: 30A: 1621-5
13. Mufti GR. Singh M. Value of random mucosal biopsies in the management of superficial bladder cancer. Eur Urol 1992: 22: 288-93
14. Kiemeney LA, Witjes JA, Heijbroek RP, Köper NP. Verbeek AL. Debruyne FM. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch SouthEast Co-operative Urological Group. Br J Urol 1994: 73: 164-71
15. Richards B. Parmar MKB, Anderson CK et al. Interpretation of biopsies of 'normal' urothelium in patients with superficial bladder cancer. Br J Urol 1991: 67: 369-75
16. Smith G, Elton RA, Chisholm GD. Newsam JE. Hargreave TB. Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or métastases. Br J Urol 1986: 58: 659-63
17. Oosterlinck W. Kurth KH, Schröder F et al. A prospective European Organisation for Research and Treatment of Cancer Genitourinary Group randomised trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, Tl papillary carcinoma of the bladder. J Urol 1993: 149: 749-52
18. Tolley DA. Hargreave TB, Smith PH et al. Effects of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J 1988: 296: 1759-61
19. Tolley DA, Parmar MKB. Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up. J Urol 1996: 155: 1233-8
20. Lamm DL. Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995: 153: 1444-50
21. Herr HW, Laudone VP, Badalament RA et al. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988: 6: 1450-5
22. Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette-Guérin therapy prevents tumour progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomised trial. J Clin Oncol 1995; 13: 1404-8
23. Parmar MKB, Friedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 1989; 142: 284-8
24. Reading J, Hall RR, Parmar MKB. The application of a prognostic factor analysis for Ta.Tl bladder cancer in routine urological practice. Br J Urol 1995; 75: 604-7
25. Hall RR, Parmar MKB, Richards AB, Smith PH. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. Br MedJ 1994; 308: 257-60
26. Lamm DL, Blumenstein BA, Crawford ED, Montie JE, Scardino P. A randomised trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205-9
27. Lamm DL. BCG in perspective: advances in the treatment of superficial bladder cancer. Eur Urol 1995; 27(suppl 1): 2-8
28. Debruyne FM, van der Meijden AP, Geboers AD et al BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of a randomised prospective trial. Urology 1988; (suppl) 31: 20
29. Vegt PD, Witjes JA, Witjes WP, Doesburg WH, Debruyne FM, van der Meijden AP. A randomised study of intravesical mitomycin C, Bacillus Calmette-Guérin Tice and Bacillus Calmette-Guérin RIVM treatment in pTa-pTl papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995; 153: 929-33
30. Lamm DL. Maintenance versus non-maintenance BCG immunotherapy of superficial bladder cancer. J Urol 1992; 147: 274A
31. Catalona WJ, Hudson MA, Gillen DP, Andriole GL, Ratliff TL. Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 1987; 137: 220-4
32. Mufti GR, Virdi JS, Hall MH. Long-term follow-up of intravesical Epodyl therapy for superficial bladder cancer. Br J Urol 1990; 65: 32-5
33. Riddle PR, Khan 0, Fitzpatrick JM, Oliver RT. Prognostic factors influencing survival of patients receiving intravesical epodyl. J Urol 1982; 127: 430-2
34. Quilty PM, Duncan W. Treatment of superficial (Tl) tumours of the bladder by radical radiotherapy. Br J Urol 1986; 58: 147-52
35. Sawczuk IS, Olsson ÇA, deVere-White R. The limited usefulness of external beam radiotherapy in the control of superficial bladder cancer. Br J Urol 1988; 61: 330-2
36. Sarosdy MF, Lamm DL. Long-term results of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer. J Urol 1989; 142: 719-22